Shaanxi Micot Pharmaceutical Technology Co., Ltd.
13
6
6
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
15.4%
2 terminated/withdrawn out of 13 trials
71.4%
-15.1% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Role: lead
MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease
Role: lead
A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Role: lead
A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke
Role: lead
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
Role: lead
Phase I Study of MT1011 Injection in Healthy Subjects
Role: lead
Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
Role: lead
A SAD/MAD Study to Evaluate the Safety, Tolerability, PK of MT200605 in Healthy Subjects
Role: lead
A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI
Role: lead
MT1002 Phase II Study in ACS Patients With PCI
Role: lead
Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics
Role: lead
Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection
Role: lead
MT1013 Clinical TRIAL In Healthy Subject
Role: lead
All 13 trials loaded